Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc., a prominent player in the biotechnology sector, is headquartered in the United States. Founded in 1996, the company has made significant strides in developing innovative cancer therapies, particularly focusing on cell cycle regulation and apoptosis. With a strong emphasis on research and development, Cyclacel is dedicated to advancing its proprietary drug candidates, including the unique oral treatment, fadraciclib, which targets specific cancer pathways. Operating primarily in the oncology space, Cyclacel has established itself as a leader in the development of novel therapeutics that address unmet medical needs. The company’s commitment to scientific excellence has garnered recognition within the industry, positioning it favourably among peers. With a robust pipeline and strategic partnerships, Cyclacel Pharmaceuticals continues to push the boundaries of cancer treatment, striving to improve patient outcomes globally.
DitchCarbon Score
How does Cyclacel Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cyclacel Pharmaceuticals, Inc.'s score of 18 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cyclacel Pharmaceuticals, Inc.'s reported carbon emissions
Cyclacel Pharmaceuticals, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their Scope 1, 2, or 3 emissions. The absence of emissions data suggests that the company may still be in the early stages of formalising its climate commitments or reporting practices. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction initiatives. Cyclacel may be exploring opportunities to align with industry standards and best practices in climate action, but specific commitments or targets have not been disclosed at this time.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cyclacel Pharmaceuticals, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
